Skip to content

Study of gut metagenomics regulation on glucose and lipid metabolism in metabolic diseases

Multiomics study for the spatiotemporal network mechanism of intestinal flora regulating the metabolic homeostasis of ''intestine liver'' axis and participating in the occurrence and development of glucose and lipid metabolism disorders

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045134
Enrollment
Unknown
Registered
2021-04-07
Start date
2021-04-20
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes and metabolic related diseases

Interventions

Sponsors

Endocrine and Metabolic Diseases Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.According to the standard diagnosis criteria of diabetes published by WHO and IDF in 1999; 2.According to the standard of obesity Obesity Task Force established in 2001, BMI >= 28k / m2.

Exclusion criteria

Exclusion criteria: 1.Patients with severe diabetes complications, such as leg ulcers, severe kidney injury, severe neurological disease, severe retinopathy, etc.; 2.Patients have taken antibiotics for 3 days or more in the past 3 months; 3.Alcoholism (drinking more than 5 times per week, with an average of more than 50 g of white wine or 500g of chinese rice wine or 5 bottles of beer each time); 4.Patients suffer from a serious mental disorder in the past 6 months; 5.Patients have thyroid dysfunction due to medical treatment for the following diseases in the past 3 months: cholecystitis, gastrointestinal ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism, etc.; 6.Patients had undergone gastrointestinal surgery, except appendicitis and hernia surgery; 7.Patients with chronic and persistent hepatitis, cirrhosis and other serious liver diseases or hepatitis B virus surface antigen (HBsAg) positive accompanied by abnormal liver function (serum alanine aminotransferase and aspartate aminotransferase are 2.5 times of the normal value); 8.Patients suffer from abnormal pituitary function; Severe organic diseases such as cancer, myocardial infarction and stroke; Infectious diseases such as tuberculosis and HIV/AIDS; 9.Weight loss in the past 3 months by drug method (such as: fluorophenylpropanol, thyroid hormone, progesterone, laxatives and traditional Chinese medicine) or surgical methods; 10.Patients can not take care of themselves, can not clearly recall, answer questions.

Design outcomes

Primary

MeasureTime frame
routine blood;routine urine;blood lipids;blood sedimentation;liver biochemical test;thyroid function (TSH, FT3, FT4);insulin;C-Peptide; serum glycosylated hemoglobin;

Countries

China

Contacts

Public ContactSong Yongfeng

Endocrine and Metabolic Diseases Hospital of Shandong First Medical University

syf198506@163.com+86 13280010726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026